Efficacy and safety of olanzapine/fluoxetine combination in the treatment of treatment-resistant depression: a meta-analysis of randomized controlled trials

被引:17
|
作者
Luan, Shuxin [1 ]
Wan, Hongquan [1 ]
Wang, Shijun [1 ]
Li, He [2 ]
Zhang, Baogang [3 ]
机构
[1] Jilin Univ, Hosp 1, Dept Mental Hlth, Changchun, Peoples R China
[2] Jilin Univ, Hosp 1, Dept Pain Med, 71 Xinmin St, Changchun 130021, Jilin, Peoples R China
[3] Jilin Univ, China Japan Union Hosp, Dept Endoscopy, 126 Xiantai St, Changchun 130033, Jilin, Peoples R China
关键词
treatment-resistant depression; olanzapine; fluoxetine; meta-analysis; STAR-ASTERISK-D; ACUTE MANIA; FLUOXETINE; OLANZAPINE; DISORDER; THERAPY; LONG; NORTRIPTYLINE; DEFINITION; OUTCOMES;
D O I
10.2147/NDT.S127453
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Whether olanzapine/fluoxetine combination (OFC) is superior to olanzapine or fluoxetine monotherapy in patients with treatment-resistant depression (TRD) remains controversial. Thus, we conducted this meta-analysis of randomized controlled trials (RCTs) to compare the efficacy and safety of OFC with olanzapine or fluoxetine monotherapy for patients with TRD. Materials and methods: RCTs published in PubMed, Embase, Web of Science, and the ClinicalTrials.gov registry were systematically reviewed to assess the efficacy and safety of OFC. Outcomes included mean changes from baseline in Montgomery-Asberg Depression Rating Scale (MADRS), Clinical Global Impression-Severity (CGI-S), Hamilton Rating Scale for Anxiety (HAM-A), Brief Psychiatric Rating Scale (BPRS) scores, response rate, remission rate, and adverse events. Results were expressed with weighted mean difference (WMD) with 95% confidence intervals (CIs) and risk ratio (RR) with 95% CIs. Results: A total of five RCTs with 3,020 patients met the inclusion criteria and were included in this meta-analysis. Compared with olanzapine or fluoxetine monotherapy, OFC was associated with greater changes from baseline in MADRS (WMD=-3.37, 95% CI: -4.76, -1.99; P < 0.001), HAM-A (WMD=-1.82, 95% CI: -2.25, - 1.40; P < 0.001), CGI-S (WMD=-0.37, 95%CI:-0.45,-0.28;P < 0.001), and BPRS scores (WMD=-1.46, 95% CI: -2.16, -0.76; P < 0.001). Moreover, OFC had significantly higher response rate (RR= 1.35, 95% CI: 1.12, 1.63; P=0.001) and remission rate (RR=1.71, 95% CI: 1.31, 2.23; P < 0.001). The incidence of treatment-related adverse events was similar between the OFC and monotherapy groups (RR= 1.01, 95% CI: 0.94, 1.08; P= 0.834). Conclusion: OFC is more effective than olanzapine or fluoxetine monotherapy in the treatment of patients with TRD. Our results provided supporting evidence for the use of OFC in TRD. However, considering the limitations in this study, more large-scale, well-designed RCTs are needed to confirm these findings.
引用
收藏
页码:609 / 620
页数:12
相关论文
共 50 条
  • [21] Effect of Sleep Disturbance on Efficacy of Esketamine in Treatment-Resistant Depression: Findings from Randomized Controlled Trials
    Borentain, Stephane
    Williamson, David
    Turkoz, Ibrahim
    Popova, Vanina
    McCall, William, V
    Mathews, Maju
    Wiegand, Frank
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2021, 17 : 3459 - 3470
  • [22] Efficacy and Safety of Theta Burst Versus Repetitive Transcranial Magnetic Stimulation for the Treatment of Depression: A Meta-Analysis of Randomized Controlled Trials
    Liu, Chaomeng
    Li, Li
    Li, Bing
    Liu, Zhi
    Xing, Wenlong
    Zhu, Kemeng
    Jin, Wenqing
    Lin, Shuo
    Tan, Weihao
    Ren, Li
    Zhang, Qinge
    NEUROMODULATION, 2023, 27 (04): : 701 - 710
  • [23] Systematic review and meta-analysis of augmentation and combination treatments for early-stage treatment-resistant depression
    Scott, Fraser
    Hampsey, Elliot
    Gnanapragasam, Sam
    Carter, Ben
    Marwood, Lindsey
    Taylor, Rachael W.
    Emre, Cansu
    Korotkova, Lora
    Martin-Dombrowski, Jonatan
    Cleare, Anthony J.
    Young, Allan H.
    Strawbridge, Rebecca
    JOURNAL OF PSYCHOPHARMACOLOGY, 2023, 37 (03) : 268 - 278
  • [24] Efficacy and tolerability of deep transcranial magnetic stimulation for treatment-resistant depression: A systematic review and meta-analysis
    Hung, Yu-Yung
    Yang, Li-Heng
    Stubbs, Bredon
    Li, Dian-Jeng
    Tseng, Ping-Tao
    Yeh, Ta-Chuan
    Chen, Tien-Yu
    Liang, Chih-Sung
    Chu, Che-Sheng
    PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2020, 99
  • [25] Olanzapine/Fluoxetine Combination in Patients With Treatment-Resistant Depression: Rapid Onset of Therapeutic Response and Its Predictive Value for Subsequent Overall Response in a Pooled Analysis of 5 Studies
    Tohen, Mauricio
    Case, Michael
    Trivedi, Madhukar H.
    Thase, Michael E.
    Burke, Scott J.
    Durell, Todd M.
    JOURNAL OF CLINICAL PSYCHIATRY, 2010, 71 (04) : 451 - 462
  • [26] The efficacy and safety of olaparib in the treatment of cancers: a meta-analysis of randomized controlled trials
    Guo, Xiao Xia
    Wu, Hong Li
    Shia, Hong Yun
    Su, Lei
    Zhang, Xi
    CANCER MANAGEMENT AND RESEARCH, 2018, 10 : 2553 - 2562
  • [27] Adjunctive antidepressants for the treatment of bipolar depression: An updated meta-analysis of randomized clinical trials
    Shafiee, Arman
    Moltazemi, Hassan
    Amini, Mohammad Javad
    Gargari, Omid Kohandel
    Safari, Farima
    Abhari, Faeze Soltani
    Jafarabady, Kyana
    Bakhtiyari, Mahmood
    ASIAN JOURNAL OF PSYCHIATRY, 2024, 91
  • [28] Efficacy and Safety of Zoledronic Acid for Treatment of Postmenopausal Osteoporosis: A Meta-Analysis of Randomized Controlled Trials
    Wang, Chao
    AMERICAN JOURNAL OF THERAPEUTICS, 2017, 24 (05) : E544 - E552
  • [29] Deep Brain Stimulation Is Effective for Treatment-Resistant Depression: A Meta-Analysis and Meta-Regression
    Hitti, Frederick L.
    Yang, Andrew I.
    Cristancho, Mario A.
    Baltuch, Gordon H.
    JOURNAL OF CLINICAL MEDICINE, 2020, 9 (09) : 1 - 14
  • [30] Optimal parameter determination of repetitive transcranial magnetic stimulation for treating treatment-resistant depression: A network meta-analysis of randomized controlled trials
    Li, Jinbiao
    Cui, Liqian
    Li, Hao
    FRONTIERS IN PSYCHIATRY, 2022, 13